文献速递乳腺癌

曲妥珠单抗德鲁替康治疗经治HER2阳性转移性乳腺癌:II期DESTINY-Breast01试验更新生存结果

Trastuzumab deruxtecan in previously treated patients with HER2-positive metastatic breast cancer: updated survival results from a phase II trial (DESTINY-Breast01).
PubMed 文献 · Ann Oncol · 2023-12-11

多中心、开放标签、单臂II期DESTINY-Breast01试验更新分析,中位随访26.5个月,184例T-DM1耐药或不耐受的HER2阳性转移性乳腺癌患者接受T-DXd 5.4 mg/kg每3周一次静脉给药。独立中心评审确认客观缓解率为62.0%(95%CI 54.5%-69.0%),中位总生存期29.1个月(95%CI 24.6-36.1个月),中位无进展生存期19.4个月(95%CI 14.1-25.0个月),中位缓解持续时间18.2个月(95%CI 15.0个月-不可评估)。

要点

  • T-DM1经治HER2阳性转移性乳腺癌中,T-DXd 5.4 mg/kg每3周一次确认客观缓解率62.0%。
  • 中位总生存期29.1个月(95%CI 24.6-36.1个月),中位无进展生存期19.4个月(95%CI 14.1-25.0个月)。
  • 药物相关治疗中出现不良事件发生率99.5%(183例),≥3级不良事件53.8%(99例),药相关间质性肺病/肺炎15.8%(29例),其中5级2.7%(5例)。

核心结论

  • 更新结果进一步证实T-DXd在重度经治HER2阳性转移性乳腺癌中具有持续抗肿瘤活性,安全性特征一致。

研究设计与样本

  • 多中心、开放标签、单臂II期DESTINY-Breast01试验,数据截止2021年3月26日,中位随访26.5个月。
  • 患者为对T-DM1耐药或不耐受的HER2阳性转移性乳腺癌,接受T-DXd 5.4 mg/kg静脉给药每3周一次,直至疾病进展、不可接受的不良事件或撤回知情同意。
  • 主要终点为独立中心评审确认的客观缓解率,次要终点包括总生存期、缓解持续时间、无进展生存期和安全性。

主要发现

  • 接受T-DXd 5.4 mg/kg每3周一次的患者(n=184)独立中心评审确认客观缓解率为62.0%(95%CI 54.5%-69.0%)。
  • 中位总生存期为29.1个月(95%CI 24.6-36.1个月)。
  • 中位无进展生存期为19.4个月(95%CI 14.1-25.0个月),中位缓解持续时间为18.2个月(95%CI 15.0个月-不可评估)。
  • 药物相关治疗中出现不良事件见于183例(99.5%),99例(53.8%)发生至少1项≥3级治疗中出现不良事件。
  • 经判定的药物相关间质性肺病/肺炎发生率为15.8%(n=29),其中2.7%(n=5)为5级。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Primary analysis of the multicenter, open-label, single-arm, phase II DESTINY-Breast01 trial (median follow-up 11.1 months) demonstrated durable antitumor activity with trastuzumab deruxtecan (T-DXd) in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (mBC) previously treated with trastuzumab emtansine (T-DM1). We report updated cumulative survival outcomes with a median follow-up of 26.5 months (data cut-off 26 March 2021). PATIENTS AND METHODS: Patients with HER2-positive mBC resistant or refractory to T-DM1 received T-DXd 5.4 mg/kg intravenously every 3 weeks until disease progression, unacceptable adverse events, or withdrawal of consent. The primary endpoint was confirmed objective response rate (ORR) by independent central review (ICR). Secondary endpoints included overall survival (OS), duration of response (DoR), progression-free survival (PFS), and safety. RESULTS: The ORR by ICR was 62.0% [95% confidence interval (CI) 54.5% to 69.0%] in patients who received T-DXd 5.4 mg/kg every 3 weeks (n = 184). Median OS was 29.1 months (95% CI 24.6-36.1 months). Median PFS and DoR were 19.4 months (95% CI 14.1-25.0 months) and 18.2 months (95% CI 15.0 months-not evaluable), respectively. Drug-related treatment-emergent adverse events (TEAEs) were observed in 183 patients (99.5%), and 99 patients (53.8%) had one or more grade ≥3 TEAEs. Adjudicated drug-related interstitial lung disease/pneumonitis occurred in 15.8% of patients (n = 29), of which 2.7% (n = 5) were grade 5. CONCLUSIONS: These updated results provide further evidence of sustained antitumor activity of T-DXd with a consistent safety profile in heavily pretreated patients with HER2-positive mBC.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Saura C, Modi S, Krop I, et al. Trastuzumab deruxtecan in previously treated patients with HER2-positive metastatic breast cancer: updated survival results from a phase II trial (DESTINY-Breast01). Ann Oncol. 2023. PMID: 38092229. doi:10.1016/j.annonc.2023.12.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。